Published online before print December 5, 2005, doi: 10.1161/CIRCULATIONAHA.105.561423
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2005;112:3738-3744.)
© 2005 American Heart Association, Inc.
Heart Failure |
Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients
From the Cardiovascular Division (S.D.S., N.A., H.S., M.A.P.), Department of Medicine, Brigham and Women’s Hospital, Boston, Mass; University of Glasgow (J.J.V.M.), Glasgow, United Kingdom; Sahlgrenska University Hospital/Östra (K.S.), Göteborg, Sweden; Hamilton Health Sciences and McMaster University (S.Y.), Hamilton, Ontario, Canada; Duke University Medical Center (C.B.G.), Durham, NC; AstraZeneca LP (E.L.M.), Wilmington, Del; and London School of Hygiene (D.W., S.P.), London, United Kingdom.
Correspondence to Scott D. Solomon, MD, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02445.
Received May 10, 2005; revision received August 9, 2005; accepted September 7, 2005.
Background— Left ventricular function is a principal determinant of cardiovascular risk in patients with heart failure. The growing number of patients with preserved systolic function heart failure underscores the importance of understanding the relationship between ejection fraction and risk.
Methods and Results— We studied 7599 patients with a broad spectrum of symptomatic heart failure enrolled in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Program. All patients were randomized to candesartan at a target dose of 32 mg once daily or matching placebo and followed up for a median of 38 months. We related left ventricular ejection fraction (LVEF), measured before randomization at the sites, to cardiovascular outcomes and causes of death. Mean LVEF in patients enrolled in CHARM was 38.8±14.9% (median LVEF 36%). Patients with lower LVEF tended to have higher baseline New York Heart Association class. The hazard ratio for all-cause mortality increased by 39% for every 10% reduction in ejection fraction below 45% (hazard ratio 1.39, 95% CI 1.32 to 1.46), with adjustment for baseline covariates. All-cause mortality, cardiovascular death, and all components of cardiovascular death declined with increasing ejection fraction until an ejection fraction of 45%, after which the risk of these outcomes remained relatively stable with increasing LVEF. The absolute change in rate per 100 patient-years for each 10% reduction in LVEF was greatest for sudden death and heart failure–related death. The effect of candesartan in reducing cardiovascular outcomes was consistent across LVEF categories.
Conclusions— LVEF is a powerful predictor of cardiovascular outcome in heart failure patients across a broad spectrum of ventricular function. Nevertheless, once elevated to a range above 45%, ejection fraction does not further contribute to assessment of cardiovascular risk in heart failure patients.
Key Words: heart failure • mortality • trials • cardiac function • ejection fraction
Related Article:
Circulation 2005 112: 3667.
This article has been cited by other articles:
 |
|
 |
|
  T K Lim, G Dwivedi, S Hayat, S Majumdar, and R Senior Independent value of left atrial volume index for the prediction of mortality in patients with suspected heart failure referred from the community Heart, July 15, 2009; 95(14): 1172 - 1178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Lee, P. Gona, R. S. Vasan, M. G. Larson, E. J. Benjamin, T. J. Wang, J. V. Tu, and D. Levy Relation of Disease Pathogenesis and Risk Factors to Heart Failure With Preserved or Reduced Ejection Fraction: Insights From the Framingham Heart Study of the National Heart, Lung, and Blood Institute Circulation, June 23, 2009; 119(24): 3070 - 3077. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. De Keulenaer and D. L. Brutsaert The Heart Failure Spectrum: Time for a Phenotype-Oriented Approach Circulation, June 23, 2009; 119(24): 3044 - 3046. [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Allen, A. F. Hernandez, C. M. O'Connor, and G. M. Felker End points for clinical trials in acute heart failure syndromes. J. Am. Coll. Cardiol., June 16, 2009; 53(24): 2248 - 2258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Amato Jr., J. L. Amato Sr., J. K. Ghali, H. Tomoda, G. Schillaci, G. Pucci, M. Pirro, B. M. Massie, P. E. Carson, and the I-PRESERVE Investigators Irbesartan for Heart Failure with Preserved Ejection Fraction N. Engl. J. Med., March 19, 2009; 360(12): 1256 - 1259. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Setoguchi, A. Nohria, J. A. Rassen, L. W. Stevenson, and S. Schneeweiss Maximum potential benefit of implantable defibrillators in preventing sudden death after hospital admission because of heart failure Can. Med. Assoc. J., March 17, 2009; 180(6): 611 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Genovesi, M. G. Valsecchi, E. Rossi, D. Pogliani, I. Acquistapace, V. De Cristofaro, A. Stella, and A. Vincenti Sudden death and associated factors in a historical cohort of chronic haemodialysis patients Nephrol. Dial. Transplant., March 16, 2009; (2009) gfp104v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Abrahamsson, J. Dobson, C. B. Granger, J. J.V. McMurray, E. L. Michelson, M. Pfeffer, S. Pocock, S. D. Solomon, S. Yusuf, K. Swedberg, et al. Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure Eur. Heart J., February 1, 2009; 30(3): 338 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Kwon, C. M. Halley, T. P. Carrigan, V. Zysek, Z. B. Popovic, R. Setser, P. Schoenhagen, R. C. Starling, S. D. Flamm, and M. Y. Desai Extent of left ventricular scar predicts outcomes in ischemic cardiomyopathy patients with significantly reduced systolic function: a delayed hyperenhancement cardiac magnetic resonance study. J. Am. Coll. Cardiol. Img., January 1, 2009; 2(1): 34 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. G. Stevenson, D. J. Wilber, A. Natale, W. M. Jackman, F. E. Marchlinski, T. Talbert, M. D. Gonzalez, S. J. Worley, E. G. Daoud, C. Hwang, et al. Irrigated Radiofrequency Catheter Ablation Guided by Electroanatomic Mapping for Recurrent Ventricular Tachycardia After Myocardial Infarction: The Multicenter Thermocool Ventricular Tachycardia Ablation Trial Circulation, December 16, 2008; 118(25): 2773 - 2782. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Henkel, M. M. Redfield, S. A. Weston, Y. Gerber, and V. L. Roger Death in Heart Failure: A Community Perspective Circ Heart Fail, July 1, 2008; 1(2): 91 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Schou, C. Torp-Pedersen, F. Gustafsson, J. Abdulla, and L. Kober Wall motion index, estimated glomerular filtration rate and mortality risk in patients with heart failure or myocardial infarction: A pooled analysis of 18,010 patients Eur J Heart Fail, July 1, 2008; 10(7): 682 - 688. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Wachtell Left ventricular systolic performance in asymptomatic aortic stenosis Eur. Heart J. Suppl., July 1, 2008; 10(suppl_E): E16 - E22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Oldenburg, A. Schmidt, B. Lamp, T. Bitter, B. G. Muntean, C. Langer, and D. Horstkotte Adaptive servoventilation improves cardiac function in patients with chronic heart failure and Cheyne-Stokes respiration Eur J Heart Fail, June 1, 2008; 10(6): 581 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L Ingle, J G F Cleland, and A L Clark Perception of symptoms is out of proportion to cardiac pathology in patients with "diastolic heart failure" Heart, June 1, 2008; 94(6): 748 - 753. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. de Mattos, A. Siedlecki, R. S. Gaston, G. J. Perry, B. A. Julian, C. E. Kew II, M. H. Deierhoi, C. Young, J. J. Curtis, and A. E. Iskandrian Systolic Dysfunction Portends Increased Mortality among Those Waiting for Renal Transplant J. Am. Soc. Nephrol., June 1, 2008; 19(6): 1191 - 1196. [Full Text] [PDF]
|
|
|
|
|
|
G Mahadevan, R C Davis, M P Frenneaux, F D R Hobbs, G Y H Lip, J E Sanderson, and M K Davies Left ventricular ejection fraction: are the revised cut-off points for defining systolic dysfunction sufficiently evidence based? Heart, April 1, 2008; 94(4): 426 - 428. [Full Text] [PDF]
|
|
|
|
|
|
W. J. Paulus, C. Tschope, J. E. Sanderson, C. Rusconi, F. A. Flachskampf, F. E. Rademakers, P. Marino, O. A. Smiseth, G. De Keulenaer, A. F. Leite-Moreira, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology Eur. Heart J., October 2, 2007; 28(20): 2539 - 2550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Solomon, J. Dobson, S. Pocock, H. Skali, J. J.V. McMurray, C. B. Granger, S. Yusuf, K. Swedberg, J. B. Young, E. L. Michelson, et al. Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure Circulation, September 25, 2007; 116(13): 1482 - 1487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. R. Pischke, G. Weidner, M. Elliott-Eller, and D. Ornish Lifestyle changes and clinical profile in coronary heart disease patients with an ejection fraction of <=40% or >40% in the Multicenter Lifestyle Demonstration Project Eur J Heart Fail, September 1, 2007; 9(9): 928 - 934. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Adamopoulos, F. Zannad, R. Fay, A. Mebazaa, A. Cohen-Solal, L. Guize, Y. Juilliere, and F. Alla Ejection fraction and blood pressure are important and interactive predictors of 4-week mortality in severe acute heart failure Eur J Heart Fail, September 1, 2007; 9(9): 935 - 941. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Duboc, C. Meune, B. Pierre, K. Wahbi, B. Eymard, A. Toutain, C. Berard, G. Vaksmann, and H.-M. Becane Perindopril preserves left ventricular function in X-linked Duchenne muscular dystrophy Eur. Heart J. Suppl., September 1, 2007; 9(suppl_E): E20 - E24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Conen, L. Melly, C. Kaufmann, S. Bilz, P. Ammann, B. Schaer, C. Sticherling, B. Muller, and S. Osswald Amiodarone-Induced Thyrotoxicosis: Clinical Course and Predictors of Outcome J. Am. Coll. Cardiol., June 19, 2007; 49(24): 2350 - 2355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Piccirillo, D. Magri, S. Matera, M. Magnanti, A. Torrini, E. Pasquazzi, E. Schifano, S. Velitti, V. Marigliano, R. Quaglione, et al. QT variability strongly predicts sudden cardiac death in asymptomatic subjects with mild or moderate left ventricular systolic dysfunction: a prospective study Eur. Heart J., June 1, 2007; 28(11): 1344 - 1350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. F. Lewis, G. A. Lamas, E. O'Meara, C. B. Granger, M. E. Dunlap, R. S. McKelvie, J. L. Probstfield, J. B. Young, E. L. Michelson, K. Halling, et al. Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM Eur J Heart Fail, January 1, 2007; 9(1): 83 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ghio Role of echo Doppler techniques in the evaluation and treatment of heart failure patients Eur. Heart J. Suppl., September 1, 2006; 8(suppl_E): E28 - E31. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Aurigemma Diastolic heart failure--a common and lethal condition by any name. N. Engl. J. Med., July 20, 2006; 355(3): 308 - 310. [Full Text] [PDF]
|
|